Alfonso Quintas Cardama - 31 Aug 2021 Form 4 Insider Report for TCR2 THERAPEUTICS INC.

Role
Chief Medical Officer
Signature
/s/ Margaret Siegel as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
31 Aug 2021
Net transactions value
+$65,979
Form type
4
Filing time
10 Dec 2021, 15:34:44 UTC
Next filing
18 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCRR Common Stock Award $2,339 +164 +4.4% $14.26* 3,915 31 Aug 2021 Direct F1, F2
transaction TCRR Common Stock Options Exercise $31,820 +43,000 +1098% $0.7400 46,915 09 Dec 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRR Stock Option (Right to Buy) Options Exercise $31,820 +43,000 $0.7400 31,582 09 Dec 2021 Common Stock 43,000 $0.7400 Direct F3
transaction TCRR Stock Option (Right to Buy) Award $0 +114,700 $0.000000 114,700 09 Dec 2021 Common Stock 114,700 $5.21 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of March 1, 2021 through August 31, 2021. This transaction is exempt under Rule 16b-3(c).
F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on August 31, 2021.
F3 25% of this option vested and became exercisable on October 10, 2018, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
F4 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter